WCM
VNDA icon

Weld Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Weld Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-27,039
Closed -$444K – 729
2019
Q4 		$444K Buy
+27,039
New +$409K 0.09% 386
2019
Q3 		– Sell
-22,300
Closed -$314K – 1028
2019
Q2 		$314K Buy
22,300
+7,402
+50% +$118K 0.06% 532
2019
Q1 		$274K Buy
+14,898
New +$339K 0.05% 529

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Weld Capital Management's VNDA Position: Q1 2020 in Review

Weld Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2020, closing a stake of 27,039 shares — an estimated $444K sold.

Weld Capital Management first reported a position in VNDA in Q1 2019 and held it in 3 quarters. The position peaked at $444K in Q4 2019. 159 funds tracked by Wall St. Rank hold VNDA as of Q1 2020.

  • Weld Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Weld Capital Management sold 27,039 Vanda Pharmaceuticals shares in Q1 2020, an estimated $444K.
  • Weld Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Weld Capital Management's Vanda Pharmaceuticals position peaked at $444K in Q4 2019.
  • 159 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2020.

Based on Weld Capital Management's 13F filing for Q1 2020, filed 15 May 2020.